AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00837655
Drug: Calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium carbonate tablets, 250 mg (Kalcidon, Abigo AB). Calcium carbonate will be prescribed at the dose given prior to the washout period. The dose will be adjusted weekly to obtain a serum phosphate concentration \<1.8 mmol/l.
Trial: NCT03096327
Drug: Montelukast
RxNorm normalized name: Montelukast
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Montelukast sodium is a selective blocker of the CysLT1 receptor. For treatment of chronic asthma, montelukast is administered once daily to adults as a 10-mg film-coated tablet, to children aged 6-14 years as a 5-mg chewable tablet, and to children aged 2-5 years as a 4-mg chewable tablet form.
Trial: NCT04127916
Drug: Bendamustine
RxNorm normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: To investigate the efficacy and safety of bendamustine plus rituximab in patients with mantle cell lymphoma.
Trial: NCT00177528
Drug: venlafaxine-XR
RxNorm normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00703885
Drug: 0.25 mg alprazolam
DrugBank: Alprazolam (DB00404)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.25 mg alprazolam PO (liquid) to be administered 1 hour prior to fMRI scan~Note that subjects receive all 3 treatments in randomized order (cross-over study), approximately 7-10 days apart.
Trial: NCT00456313
Drug: FLIXOTIDE and SERETIDE
RxNorm normalized name: cytarabine and daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: comparator
Trial: NCT02607410
Drug: sitagliptin
RxNorm normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: patients with type 2 diabetes,inadequately controlled with metformin plus glyburide, HbA1c between 6.6 to 10%, will be randomized to the addition of sitagliptin (Sitagliptin Group) or of bedtime NPH insulin (NPH Group) during one year
Trial: NCT02709720
Drug: Vinorelbine
RxNorm normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cycle 1 and 2 50 mg/day, (Monday, Wednesday and Friday)
Trial: NCT02709720
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cycle 1 and 2 day 1, 80 mg/m2
Trial: NCT02709720
Drug: Vinorelbine
RxNorm normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cycle 3 and 4 30 mg/day, (Monday, Wednesday and Friday)
Trial: NCT02709720
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cycle 3 and 4 day 1, 80 mg/m2
Trial: NCT01718158
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01718158
Drug: Daclatasvir
RxNorm normalized name: Daclatasvir
DrugBank: Daclatasvir (DB09102)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01718158
Drug: Telaprevir
RxNorm normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01823081
Drug: Intravitreal injection of bevacizumab (Avastin)
RxNorm normalized name: bevacizumab Injection
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01823081
Drug: Intravitreal injection of fasudil and bevacizumab (Avastin)
RxNorm normalized name: bevacizumab Injection
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: intravitreal injections of bevacizumab and fasudil are performed at two different sites (superior temporal and inferior temporal quadrants respectively)
Trial: NCT02615119
Drug: Isoproterenol
RxNorm normalized name: Isoproterenol
DrugBank: Isoprenaline (DB01064)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous infusions of isoproterenol, delivered in a randomized double blinded order, in each participant from each group. Participants will rate the experience of heartbeat and breathing sensations as well as anxiety induced by the infusion.
Trial: NCT00703885
Drug: 1.0 mg alprazolam
DrugBank: Alprazolam (DB00404)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 mg alprazolam PO (liquid) will be administered 1 hour prior to fMRI scan~Note that subjects receive all 3 treatments in randomized order (cross-over study), approximately 7-10 days apart.
Trial: NCT00352521
Drug: bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00352521
Drug: irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02398201
Drug: Bezafibrate
RxNorm normalized name: bezafibrate
DrugBank: Bezafibrate (DB01393)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bezafibrate 200mg-600mg three times daily for 12 weeks.
Trial: NCT03685084
Drug: Piperacillin i.v.
DrugBank: Piperacillin (DB00319)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: piperacillin 3 g i.v.
Trial: NCT03685084
Drug: Cefepime i.v.
DrugBank: Cefepime (DB01413)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: cefepime 1 g i.v.
Trial: NCT00001442
Drug: paclitaxel concurrent with radiation therapy
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00629499
Drug: nab paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 100 mg/m2 of intravenous (IV) nab paclitaxel weekly (i.e., on Days 1, 8, and 15 of each 3 week treatment cycle)
Trial: NCT00629499
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 8 mg/kg loading dose of IV trastuzumab will be administered on Day 1, followed by doses of 6 mg/kg IV trastuzumab once every 3 weeks.
Trial: NCT02730572
Drug: Concerta
RxNorm normalized name: Concerta
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This is an observational study. Participants who have been on Concerta for at least 60 days will be observed.
Trial: NCT00180895
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT04105998
Drug: Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin 10 IU
Trial: NCT01540708
Drug: SERETIDE Rotacaps
RxNorm normalized name: seractide
DrugBank: Seractide acetate (DB09334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The study will be conducted in 3 parts with an adaptive design where pharmacokinetic data analysis follows each part to enable a decision on whether progression to the subsequent parts is required. Thirty six subjects will be enrolled in each part. Part A will test an alternative version of the Rotahaler with a lower airflow resistance. The study will then test one or more of the following options depending on the outcome of part A. If progressed, part B will test modified Rotacap formulations including: (1) modified blend formulation, (2) reduced capsule fill weights, (3) different capsule types. Part B will also test other versions of the Rotahaler with intermediate airflow resistance. Part C will test the lower strength FP/salmeterol (100/50 mcg or lower) and/or a new unit dose DPI device (BUDI). In each arm, subjects will be administered 7 doses (3.5 days bid) with PK sampling following administration of the 7th dose on the morning of Day 4.
Trial: NCT01540708
Drug: SERETIDE Diskus
RxNorm normalized name: seractide
DrugBank: Seractide acetate (DB09334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The study will be conducted in 3 parts with an adaptive design where pharmacokinetic data analysis follows each part to enable a decision on whether progression to the subsequent parts is required. Thirty six subjects will be enrolled in each part. Part A will test an alternative version of the Rotahaler with a lower airflow resistance. The study will then test one or more of the following options depending on the outcome of part A. If progressed, part B will test modified Rotacap formulations including: (1) modified blend formulation, (2) reduced capsule fill weights, (3) different capsule types. Part B will also test other versions of the Rotahaler with intermediate airflow resistance. Part C will test the lower strength FP/salmeterol (100/50 mcg or lower) and/or a new unit dose DPI device (BUDI). In each arm, subjects will be administered 7 doses (3.5 days bid) with PK sampling following administration of the 7th dose on the morning of Day 4.
Trial: NCT01923454
Drug: Acetazolamide
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All participants will receive oral acetazolamide (250 mg) 1 tablet at 1 hour after paracentesis to lower the intraocular pressure. After that, the dose of acetazolamide will be adjusted according to the level of intraocular pressure. If the eye pressure goes to normal (lower than 21 mmHg), acetazolamide will be discontinued.
Trial: NCT01510379
Drug: IV ondansetron 4 mg q 6 hours for a total of 4 doses
RxNorm normalized name: ondansetron 4 MG
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01510379
Drug: IV promethazine 25 mg q 6 hours prn
RxNorm normalized name: promethazine hydrochloride 6.25 MG
DrugBank: Promethazine (DB01069)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01510379
Drug: Elixir promethazine 25 mg q 6 hours prn after discharge
DrugBank: Promethazine (DB01069)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01152801
Drug: Everolimus (RAD001)
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT04704713
Drug: Afamelanotide
RxNorm normalized name: Afamelanotide
DrugBank: Afamelanotide (DB04931)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00648648
Drug: adavosertib
RxNorm normalized name: Adavosertib
DrugBank: Adavosertib (DB11740)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: adavosertib administered as an oral formulation as either monotherapy or in combination with either gemcitabine, cisplatin, or carboplatin.
Trial: NCT00648648
Drug: gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine administered at 1000 mg/m\^2 by IV infusion in a 28-day cycle.
Trial: NCT00648648
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin administered at 75 mg/m\^2 by IV infusion in a 21-day cycle.
Trial: NCT00648648
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin administered at AUC/time curve of 5 mg/min/mL (AUC5) by IV infusion in a 21-day cycle.
Trial: NCT04770688
Drug: Osimertinib
RxNorm normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Osimertinib, 80mg, QD, p.o.
Trial: NCT04770688
Drug: Anlotinib
RxNorm normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (Phase Ib) Anlotinib, from 8mg to10mg to 12mg, QD, p.o. from day 1 to 14 of a 21-day cycle.~(Phase IIa)Anlotinib, given at RP2D dose QD, p.o. from day 1 to 14 of a 21-day cycle.
Trial: NCT01469481
Drug: PF-04991532
RxNorm normalized name: PF-04991532
DrugBank: PF-04991532 (DB11765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a single oral dose of \[14C\]PF-04991532 (450 mg/100 uCi suspension)
Trial: NCT00550186
Drug: Ringers Lactate
RxNorm normalized name: magnesium sulf/ringers lactate 40 gram/500 mL INTRAVEN PLASTIC BAG, INJECTION (ML)
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01005641
Drug: exemestane
RxNorm normalized name: Exemestane
DrugBank: Exemestane (DB00990)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 mg daily
Trial: NCT01005641
Drug: lapatinib
RxNorm normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: taken orally, daily, at dose recommended after dose finding part of study
Trial: NCT02076529
Drug: Ramosetron 0.3mg
DrugBank: Ramosetron (DB09290)
FDA approved: no
EMA approved: no
PMDA approved: yes
Trial: NCT02076529
Drug: Ramosetron 0.45mg
DrugBank: Ramosetron (DB09290)
FDA approved: no
EMA approved: no
PMDA approved: yes
Trial: NCT02076529
Drug: Ramosetron 0.6mg
DrugBank: Ramosetron (DB09290)
FDA approved: no
EMA approved: no
PMDA approved: yes
Trial: NCT02776605
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone 60 mg/m2/day IV over 7 days (-7 a -1) and triple intrathecal therapy (TIT)
Trial: NCT02776605
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vincristine (VCR): 1.5 mg/m2 (maximum 2 mg) IV days 1, 8, 15 and 22.
Trial: NCT02776605
Drug: Daunorubicin
RxNorm normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daunorubicin (DNR): 45 mg/m2 IV days 1, 8, 15 and 22.
Trial: NCT02776605
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone (PDN): 60 mg/m2/day, IV or PO, days 1 to 27.
Trial: NCT02776605
Drug: Ponatinib
RxNorm normalized name: Ponatinib
DrugBank: Ponatinib (DB08901)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ponatinib 30 mg, PO from day 1 to consolidation
Trial: NCT02776605
Drug: VP-16
RxNorm normalized name: Provp-16i
DrugBank: Etoposide toniribate (DB17255)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VP-16: 100 mg/m2/12 h, IV, days 14 and 42
Trial: NCT02776605
Drug: TIT
RxNorm normalized name: Lactitol
DrugBank: Lactitol (DB12942)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TIT (MTX: 12 mg, ARA-C: 30 mg, hydrocortisone: 20 mg), , days 1, 28 and 56.
Trial: NCT02776605
Drug: Ponatinib
RxNorm normalized name: Ponatinib
DrugBank: Ponatinib (DB08901)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ponatinib 30 mg/d PO, from day 1 to 15 days before HSCT.
Trial: NCT01171651
Drug: JX-594 followed by sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive a total dose of 1e9 per treatment starting with one IV dose on Day 1 and injected intratumorally in 1-5 intrahepatic tumors on Day 8 and 22. Starting on Day 25 (3 days after the final JX-594 dose) patients will initiate oral sorafenib therapy twice daily according to standard approved guidelines. An optional maintenance JX-594 dose may be given intratumorally at Week 12 (sorafenib briefly interrupted).
Trial: NCT03773302
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine 1000 mg/m2 IV D1 and D8 for a 21-day cycle. Participants who experience disease progression while receiving gemcitabine + cisplatin will be allowed to cross over and receive infigratinib.
Trial: NCT03773302
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 25 mg/m2 IV D1 and D8 for a 21-day cycle. Participants who experience disease progression while receiving gemcitabine + cisplatin will be allowed to cross over and receive infigratinib.
Trial: NCT03841734
Drug: treatment
RxNorm normalized name: Acne Treatment
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 patients will be treat with bosentan at 145 mg per day during 14 days
Trial: NCT02478242
Drug: Nafamostat mesilate
RxNorm normalized name: mesylate
DrugBank: Nafamostat (DB12598)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: nafamostat mesilate use for anticoagulation
Trial: NCT00700622
Drug: Technosphere Insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Technosphere Insulin Inhalation Powder 15U or 30U
Trial: NCT00700622
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lantus-injectible supplied as 3mL (300 units) pens
Trial: NCT00700622
Drug: Insulin lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Humalog autopen cartridges pre-filled with 3mL (300 units)
Trial: NCT04388215
Drug: CKD-828
RxNorm normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally, 1 tablet once a day for 8 weeks
Trial: NCT04388215
Drug: CKD-828(placebo)
RxNorm normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally, 1 tablet once a day for 8 weeks
Trial: NCT04388215
Drug: D326
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: orally, 1 tablet once a day for 8 weeks
Trial: NCT04388215
Drug: D337
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: orally, 1 tablet once a day for 8 weeks
Trial: NCT04388215
Drug: D013
RxNorm normalized name: MGD013 dual-affinity re-targeting (DART)
DrugBank: Tebotelimab (DB16685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally, 1 tablet once a day for 8 weeks
Trial: NCT00290719
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00290719
Drug: gefitinib
RxNorm normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00290719
Drug: irinotecan hydrochloride
RxNorm normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03005236
Drug: ENVARSUS
RxNorm normalized name: Envarsus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Envarsus is a once-a-day oral formulation of tacrolimus.
Trial: NCT03005236
Drug: Standard twice daily tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard tacrolimus will include twice-daily formulations that are currently available.
Trial: NCT02882191
Drug: LevoCept
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: placement of LevoCept IUD
Trial: NCT00220155
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01206140
Drug: Selumetinib
RxNorm normalized name: SELUMETINIB
DrugBank: Selumetinib (DB11689)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01206140
Drug: Temsirolimus
RxNorm normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given IV
Trial: NCT00088270
Drug: OSI-7904L
RxNorm normalized name: OSI-7904L
DrugBank: OSI-7904L (DB05457)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04089527
Drug: CC-95775
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC-95775
Trial: NCT00886860
Drug: misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: misoprostol 50 micrograms oral every 4 hours until cervical dilatation 3 cm
Trial: NCT00886860
Drug: misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: misoprostol 20 micrograms oral every hours until cervical dilatation 3 cm
Trial: NCT03268889
Drug: Chidamide
RxNorm normalized name: Chidamide
DrugBank: Tucidinostat (DB06334)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Chidamide is given to the patients in this study along with CHOP regimen, to access the efficacy and safety in this cohort of PTCL patients. The dosage of the above regimen is as follows: Chidamide, 30mg,po,biw; Cyclophosphamide 750mg/m2, ivgtt, d1; Epirubicin 70mg/ m2, ivgtt, d1; Vincristine 3mg/ m2, ivgtt, d1; Prednisone 100mg/ m2, po, d1-5.
Trial: NCT01799057
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants randomized to metformin will be treated at a maximum dose of 2000mg per day (i.e. 1000mg twice daily for 16-18 weeks; up-titrated from 500mg twice daily for the first 2 weeks). Participants may complete the 16-18 week treatment intervention at the lower dose of 500mg twice daily if limited by side effects.
Trial: NCT00004215
Drug: cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00004215
Drug: daunorubicin hydrochloride
RxNorm normalized name: Daunorubicin Hydrochloride
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04544644
Drug: AK104+anlotinib
RxNorm normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AK 104 is given by intravenous infusion and anlotinib is given by oral.
Trial: NCT01174979
Drug: Caroverin
RxNorm normalized name: caroverine
DrugBank: Caroverine (DB13835)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment with eardrops 2 times for 48 hours
Trial: NCT01413711
Drug: Vigabatrin
RxNorm normalized name: Vigabatrin
DrugBank: Vigabatrin (DB01080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral vigabatrin as a single 25 mg/kg dose on Days 1 and 5, 25 mg/kg twice a day (50 mg/kg daily dose, orally) on Days 2-4
Trial: NCT01109615
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 400 mg/m2 on day 1 of a 3 weeks cycle
Trial: NCT01109615
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m2 intravenously on day 1 and 8 of a 3 weeks cycle